MA32486B1 - Derives de 4,5- dihydrooxazol-2-yle - Google Patents

Derives de 4,5- dihydrooxazol-2-yle

Info

Publication number
MA32486B1
MA32486B1 MA33533A MA33533A MA32486B1 MA 32486 B1 MA32486 B1 MA 32486B1 MA 33533 A MA33533 A MA 33533A MA 33533 A MA33533 A MA 33533A MA 32486 B1 MA32486 B1 MA 32486B1
Authority
MA
Morocco
Prior art keywords
disorders
halogen
lower alkyl
chr
substituted
Prior art date
Application number
MA33533A
Other languages
Arabic (ar)
English (en)
Inventor
Guido Galley
Annick Goergler
Zbinden Katrin Groebke
Roger Norcross
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41066683&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32486(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA32486B1 publication Critical patent/MA32486B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/28—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Cette invention concerne des composés de formule (i), r1 étant hydrogène, alkyle inférieur, alcoxy inférieur, alkyle inférieur substitué par halogène, alcoxy inférieur substitué par halogène, halogène, cyano, nitro, hydroxy, c(o)o-alkyle inférieur, s(o)2-alkyle inférieur, c(o)och2-phényle, och2-phényle, tétrazol-1-yl, phényle éventuellement substitué par halogène, ou est phényloxy éventuellement substitué par halogène, ou est benzyle éventuellement substitué par halogène ou est benzyloxy éventuellement substitué par halogène, les substituants de n > 1 pouvant être identiques ou différents; x est -o-(ch2)2-, -o-chr'-ch2-, -o-ch2-chr', -o-cr''2-ch2-, -(ch2)2-chr', -chr'-(ch2)2-, -cr » 2-(ch2)2-, -ch2-chr'-ch2-, -ch2-cr''2-ch2-, -chr »-o-ch2-, -ch2-o-ch2-, -cr''2-o-ch2-, -cf2(ch2)2-, -cr » 2-ch2-, -sir » 2-(ch2)2-, -s-(ch2)2-, -s(o)2-(ch2)2-, -(ch2)4-, -ch2-o-(ch2)2-, lorsque m vaut 0, 1, 2 ou 3; r' est alkyle inférieur, alcoxy inférieur ou alkyle inférieur substitué par halogène; r'' est alkyle inférieur ou alkyle inférieur substitué par halogène; r2 est hydrogène ou alkyle inférieur; y est aryle, cycloalkyle ou hétéroaryle; n vaut 1, 2 ou 3; ou un sel d'addition acide pharmaceutiquement approprié. Les composés décrits dans la formule (i) peuvent être utilisés dans le traitement de maladies associées à la fonction biologique des récepteurs associés à une amine de trace, lesdites maladies étant la dépression, les troubles de l'angoisse, les troubles bipolaires, les troubles déficitaires de l'attention avec hyperactivité, les troubles associés au stress, les troubles psychotiques, la schizophrénie, les maladies neurologiques, la maladie de parkinson, les troubles neurodégénératifs, la maladie d'alzheimer, l'épilepsie, la migraine, la toxicomanie et les troubles métaboliques, les troubles de l'alimentation, le diabète, les complications diabétiques, l'obésité, la dyslipidémie, les troubles de la consommation et de l'assimilation énergétique, les troubles et les dysfonctionnements de l'homéostasie (température corporelle), les troubles du sommeil et du rythme circadien et les affections cardiovasculaires.
MA33533A 2008-07-24 2011-01-18 Derives de 4,5- dihydrooxazol-2-yle MA32486B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08161060 2008-07-24
PCT/EP2009/059026 WO2010010014A1 (fr) 2008-07-24 2009-07-15 Dérivés de 4,5-dihydrooxazol-2-yle

Publications (1)

Publication Number Publication Date
MA32486B1 true MA32486B1 (fr) 2011-07-03

Family

ID=41066683

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33533A MA32486B1 (fr) 2008-07-24 2011-01-18 Derives de 4,5- dihydrooxazol-2-yle

Country Status (22)

Country Link
US (2) US20100041686A1 (fr)
EP (1) EP2321287B1 (fr)
JP (1) JP5547187B2 (fr)
KR (1) KR101307007B1 (fr)
CN (1) CN102083805A (fr)
AR (1) AR072876A1 (fr)
AU (1) AU2009273324A1 (fr)
BR (1) BRPI0916363A2 (fr)
CA (1) CA2728480A1 (fr)
CL (1) CL2011000137A1 (fr)
CO (1) CO6331336A2 (fr)
CR (1) CR11843A (fr)
EC (1) ECSP11010782A (fr)
ES (1) ES2556633T3 (fr)
IL (1) IL209423A0 (fr)
MA (1) MA32486B1 (fr)
MX (1) MX2011000464A (fr)
PE (1) PE20110215A1 (fr)
RU (1) RU2513086C2 (fr)
TW (1) TW201008916A (fr)
WO (1) WO2010010014A1 (fr)
ZA (1) ZA201008657B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2736130C (fr) 2008-09-11 2014-01-14 Amgen Inc. Composes cycliques spiro-tetracycliques utiles en tant que modulateurs de la beta-secretase et leurs procedes d'utilisation
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
AU2011227501B9 (en) 2010-03-15 2013-08-22 Amgen Inc. Amino -dihydrooxazine and amino - dihydrothiazine spiro compounds as Beta - secretase modulators and their medical use
WO2011115938A1 (fr) 2010-03-15 2011-09-22 Amgen Inc. Composés spiro tétracycliques en tant que modulateurs de la béta-sécrétase
US9132136B2 (en) 2010-08-02 2015-09-15 Hoffmann-La Roche Inc. Pharmaceutical combination
US8673950B2 (en) * 2010-11-02 2014-03-18 Hoffmann-Laroche Inc. Dihydrooxazol-2-amine derivatives
US9346827B2 (en) 2011-02-07 2016-05-24 Amgen Inc. 5-amino-oxazepine and 5-amino-thiazepane compounds as beta secretase antagonists and methods of use
US9296759B2 (en) 2011-09-21 2016-03-29 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
WO2014078314A1 (fr) 2012-11-15 2014-05-22 Amgen Inc. Composés d'amino-oxazine et d'amino-dihydrothiazine jouant le rôle de modulateurs de bêta-sécrétase et procédés d'utilisation
MY195528A (en) 2016-03-17 2023-01-30 Hoffmann La Roche 5-Ethyl-4-Methyl-Pyrazole-3-Carboxamide Derivative Having Activity as Agonist of Taar
WO2017192858A1 (fr) * 2016-05-04 2017-11-09 Purdue Pharma L.P. Pseudodimères d'oxazoline, compositions pharmaceutiques et utilisation correspondantes
EP3463359A4 (fr) * 2016-06-02 2020-08-26 Purdue Pharma LP Agonistes du récepteur 1 associé à une amine à l'état de trace et agonistes partiels pour le traitement de la douleur

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2731471A (en) * 1956-01-17 Nxg hi
US2161938A (en) * 1934-07-31 1939-06-13 Soc Of Chemical Ind Imidazolines
US2457047A (en) * 1946-02-13 1948-12-21 Monsanto Chemicals 2-(2'-thenyl)-4, 5-dihydroimidazoles and process for making the same
US2778836A (en) * 1954-04-02 1957-01-22 Union Chimique Belge Sa Substituted 2-methyl-delta2 imidazolines
US2744910A (en) * 1955-06-27 1956-05-08 Bristol Lab Inc 2-(ortho-benzylbenzyl)-imidazoline and acid addition salts
US2744909A (en) * 1955-06-27 1956-05-08 Bristol Lab Inc 2-(ortho-phenylbenzyl) imidazoline and acid addition salts
US2919274A (en) * 1957-09-17 1959-12-29 Sahyun Melville Amidines
DE1121054B (de) * 1960-11-23 1962-01-04 Merck Ag E Verfahren zur Herstellung eines neuen Imidazolinderivates und dessen Saeureadditionssalzen
DE1150180B (de) * 1962-04-12 1963-06-12 Merck Ag E Mittel zur Vorbehandlung der Haut fuer die Rasur
US3377247A (en) * 1967-04-28 1968-04-09 Dow Chemical Co Antidepressant method
US3586695A (en) * 1968-01-26 1971-06-22 Dow Chemical Co Substituted imidazolinyl indoles
US3577428A (en) 1969-04-14 1971-05-04 Colgate Palmolive Co 2-amino-4-aryloxyalkyl-4-alkyl-2-oxazolines
BE754820R (fr) * 1969-08-13 1971-02-15 Schering Ag Nouveaux derives de pyrimidine, leurs procedes de preparation et leurs
US3622579A (en) * 1969-08-28 1971-11-23 Boehringer Sohn Ingelheim Derivatives of 2-anilino-1,3-diazacyclopentene-(2)
US3818094A (en) * 1969-08-28 1974-06-18 Boehringer Sohn Ingelheim Hypotensive pharmaceutical compositions containing certain 2-anilino-1,3-diazacyclopentenes-(2)
US3660423A (en) * 1970-02-13 1972-05-02 Dow Chemical Co 2-(substituted benzyl)methyl-2-imidazolines
GB1333471A (en) * 1971-01-27 1973-10-10 Labaz Imidazoline derivatives and process for preparing the same
US4125620A (en) * 1974-10-01 1978-11-14 Boehringer Ingelheim Gmbh 2-[(2',6'-Disubstituted-phenyl)-imino]-imidazolidines and salts thereof
US3992403A (en) * 1975-05-30 1976-11-16 Schering Corporation 2-Imidazolines and their use as hypoglycemic agents
GB1538097A (en) * 1976-01-26 1979-01-10 Lafon Labor Substituted phenyl-amidines
US4323570A (en) * 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
US4311840A (en) * 1980-11-13 1982-01-19 E. R. Squibb & Sons, Inc. 2,3,6,7-Tetrahydro-2-thioxo-4H-oxazolo[3,2-a]-1,3,5 triazin-4-ones
EP0096297B1 (fr) * 1982-06-03 1988-06-15 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Procédé de préparation de dérivés de 1-sulfo-2-oxoazétidine
DK302185A (da) * 1984-07-05 1986-01-06 Rolland Sa A 2-amino-oxazoliner samt fremgangsmaade til deres fremstilling
US4665095A (en) * 1985-12-11 1987-05-12 Abbott Laboratories Use of 2-[(3,5-dihalo-4-aminobenzyl)]imidazolines to stimulate alpha-1 adrenergic receptors and to treat nasal congestion
GB9425211D0 (en) * 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
DE19514579A1 (de) * 1995-04-20 1996-10-24 Boehringer Ingelheim Kg Verwendung von alpha¶1¶¶L¶-Agonisten zur Behandlung der Harninkontinenz
US5610174A (en) * 1995-06-02 1997-03-11 Synaptic Pharmaceutical Corporation Use of α1A -selective adrenoceptor agonists for the treatment of urinary incontinence
US5866579A (en) * 1997-04-11 1999-02-02 Synaptic Pharmaceutical Corporation Imidazole and imidazoline derivatives and uses thereof
ATE293102T1 (de) * 1998-04-23 2005-04-15 Takeda Pharmaceutical Naphthalene derivate ,ihre herstellung und verwendung
IL147921A0 (en) * 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
CA2581828A1 (fr) * 2004-09-24 2006-04-06 Allergan, Inc. 4-(heteroaryl-methyl et heteroaryl-methyl substitue)-imidazole-2-thiones utilisees en tant qu'agonistes des alpha2 adrenergiques
KR101079914B1 (ko) * 2006-01-27 2011-11-04 에프. 호프만-라 로슈 아게 중추신경계 장애를 위한 4-이미다졸 유도체의 용도
ES2510546T3 (es) * 2007-02-02 2014-10-21 F. Hoffmann-La Roche Ag Nuevas 2-aminooxazolinas como ligandos TAAR1 para trastornos del SNC

Also Published As

Publication number Publication date
AR072876A1 (es) 2010-09-29
WO2010010014A1 (fr) 2010-01-28
CO6331336A2 (es) 2011-10-20
CN102083805A (zh) 2011-06-01
PE20110215A1 (es) 2011-03-31
ZA201008657B (en) 2011-10-26
ES2556633T3 (es) 2016-01-19
JP2011528685A (ja) 2011-11-24
ECSP11010782A (es) 2011-02-28
RU2011104433A (ru) 2012-08-27
KR101307007B1 (ko) 2013-09-11
AU2009273324A1 (en) 2010-01-28
KR20110020936A (ko) 2011-03-03
TW201008916A (en) 2010-03-01
CL2011000137A1 (es) 2011-07-15
JP5547187B2 (ja) 2014-07-09
CR11843A (es) 2011-02-16
MX2011000464A (es) 2011-03-01
CA2728480A1 (fr) 2010-01-28
EP2321287A1 (fr) 2011-05-18
BRPI0916363A2 (pt) 2018-05-29
RU2513086C2 (ru) 2014-04-20
EP2321287B1 (fr) 2015-11-11
IL209423A0 (en) 2011-01-31
US20120165294A1 (en) 2012-06-28
US20100041686A1 (en) 2010-02-18

Similar Documents

Publication Publication Date Title
MA35194B1 (fr) Derives de benzamide substitues
MA35192B1 (fr) Derives de pyrazole
MA35062B1 (fr) Dérivés d'amines hétérocycliques
MA33855B1 (fr) Dérivés de benzamide substitués
MA31165B1 (fr) Nouvelles 2-aminooxazolines servant de ligands du taar1 pour des troubles du snc
ECSP11010782A (es) Derivados de 4,5-dihidro-oxazol-2-ilo
US20220024875A1 (en) Process for the manufacturing of (6ar,10ar)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4',5':5,6]benzo[1,2-g]quinoline and (4ar,10ar)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[g]quinoline-6,7-diol
JP2008013556A (ja) 新規ナフタレン化合物、その製造法、およびそれを含有する薬学的組成物
CN1074766C (zh) 烷氨基苯并噻唑及－苯并噁唑衍生物
TW200738645A (en) Use of 4-imidazole derivatives for CNS disorders
WO2009003868A3 (fr) 2-imidazolines
MX354815B (es) Derivados heterociclicos como receptores asociados con las aminas traza (taars).
MX2009003887A (es) Aminometil-2-imidazoles con afinidad con los receptores asociados a trazas de amina.
MA37944A1 (fr) Dérivés de pyrazole-carboxamide en tant que modulateurs de taar pour utilisation dans le traitement de plusieurs troubles, tels que la dépression, le diabète et la maladie de parkinson
TW200738690A (en) Use of 2-imidazoles for the treatment of CNS disorders
MX2009005920A (es) Nuevos 2-imidazoles como ligandos para receptores asociados con trazas de amina.
MX2009006215A (es) 4-imidazolinas como ligandos de aminas trazas.
MX2009013745A (es) 4-imidazolinas y su uso como antidepresivos.
WO2007090720A3 (fr) Utilisation de 2-imidazoles pour le traitement de troubles du système nerveux central
JP5571072B2 (ja) アルファアドレナリン介在症状の治療方法
MX349738B (es) Derivados de dihidrooxazol-2-amina.
CN1087015C (zh) 吡啶衍生物
MX2009005047A (es) 4-imidazoles sustituidos.
MX2015005721A (es) Derivados de pirazina.
CN102993203B (zh) 8-苯基黄嘌呤类衍生物的制备及应用